Pfizer, Starboard
Starboard Value CEO says Pfizer's board should hold management accountable
Activist hedge fund Starboard Value's chief executive officer said on Tuesday that drugmaker Pfizer's board needs to hold management accountable for its underperformance, particularly for its record for producing profitable new drugs.
UPDATED: Starboard wants to hold Pfizer leadership 'accountable' for overpaid M&A deals, poor return on R&D investment
Activist investor Starboard Value is baring its teeth at Pfizer management, more openly going after CEO Albert Bourla’s job. | Activist investor Starboard Value is baring its teeth at Pfizer management,
Starboard's Jeff Smith told Pfizer in a meeting last week that they need to improve their return on investments in R&D and ...
Starboard has a $1 billion stake in Pfizer and an unknown but "sizable" stake in Kenvue, according to earlier media reports.
Despite that cash windfall, Pfizer has "dramatically underperformed its peers and the market since 2019," according to ...
Investor's Business Daily on MSN15h
Starboard Hammers Pfizer Execs For Failing To Deliver On 'Best Pipeline' PromisesStarboard took aim at Pfizer in another blow Tuesday, saying the company has failed to deliver on what it called the "best ...
Starboard Value criticizes Pfizer's leadership for underperformance, citing a 50% stock decline and missed growth targets ...
The activist investor claims Pfizer failed to capitalize on the windfall earned from its COVID-19 vaccine and, in the process, destroyed tens of billions of dollars in market value.
The corporate clash between Pfizer and Starboard Value heated up on Thursday when the activist investment firm pressed the ...
Activist hedge fund Starboard Value believes the root cause of Pfizer’s issues are the low expected returns on its research and development investments, including investments done both internally and ...
Starboard Value contends that Kenvue, with strong consumer health brands like Tylenol and Listerine, is underperforming its ...
Starboard Value LP Chief Executive Officer Jeffrey Smith said there has been at least $20 billion in value destruction at drugmaker Pfizer Inc., which he admonished for failing to deliver on a ...
20hon MSN
Jeff Smith, Starboard Value CEO, joins CNBC's 'Squawk on the Street' to discuss how he sees Pfizer going forward, potential ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback